Larry Mathis Financial Planning LLC Purchases Shares of 4,834 Gilead Sciences, Inc. $GILD

Larry Mathis Financial Planning LLC acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 4,834 shares of the biopharmaceutical company’s stock, valued at approximately $593,000.

Several other large investors have also made changes to their positions in the business. Norges Bank bought a new position in Gilead Sciences in the 4th quarter worth approximately $2,617,152,000. Boston Partners bought a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $517,808,000. Massachusetts Financial Services Co. MA boosted its position in shares of Gilead Sciences by 3,763.8% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock valued at $518,368,000 after acquiring an additional 4,113,999 shares during the period. Bank of America Corp DE grew its stake in shares of Gilead Sciences by 15.2% in the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after acquiring an additional 3,046,688 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Gilead Sciences by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after acquiring an additional 2,113,692 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $131.46, for a total value of $1,971,900.00. Following the completion of the transaction, the chief executive officer owned 617,567 shares of the company’s stock, valued at $81,185,357.82. This represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $123.92, for a total transaction of $371,760.00. Following the transaction, the insider owned 124,234 shares of the company’s stock, valued at approximately $15,395,077.28. This represents a 2.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 68,000 shares of company stock worth $8,930,150. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $123.76 on Friday. The firm has a market capitalization of $153.66 billion, a price-to-earnings ratio of 16.86 and a beta of 0.31. Gilead Sciences, Inc. has a one year low of $104.46 and a one year high of $157.29. The business has a fifty day simple moving average of $131.66 and a 200 day simple moving average of $134.21. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post -0.8 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Analyst Ratings Changes

Several equities analysts recently commented on GILD shares. Weiss Ratings cut shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, May 28th. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a research report on Tuesday. Daiwa Securities Group dropped their price objective on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Citigroup upped their price objective on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Finally, Leerink Partners reduced their target price on shares of Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. Twenty-five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $158.41.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.